StockData

IDEXX Laboratories vs Lantheus

IDXX and LNTH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IDXX and LNTH compare

IDEXX Laboratories is the larger company, worth 8.2 times as much as Lantheus ($54.4B against $6.6B).

On earnings, Lantheus is cheaper: it trades at 24.6× trailing earnings, against 48.5× for IDEXX Laboratories.

IDEXX Laboratories grew revenue faster over the last twelve months (12.8% versus 2.3% for Lantheus).

IDEXX Laboratories keeps more of each dollar of sales as profit, with a net margin of 25.0% compared with 17.7% at Lantheus.

IDEXX Laboratories scores higher on the StockData Score (19 against 11 for Lantheus), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIDXXLNTH
Size and price
Market cap$54.4B$6.6B
Share price$690.24$101.80
Change, 1 year0.04%92.0%
Change, 5 years13.6%265%
Beta (5Y)0.340.41
Employees11K1,193
StockData Score
Total score19 (better)11
Valuation score2 (better)0
Growth score5 (better)2
Performance score6 (better)5
Health score6 (better)4
Dividend score00
Valuation
P/E48.5×24.6× (better)
P/S11.9×4.3× (better)
P/B33.7×5.1× (better)
EV/EBITDA33.9×16.9× (better)
P/FCF43.4×–
PEG2.750.24 (better)
FCF yield2.3%–
Fair value$509.32$91.02
Margin of safety−35.5%−11.8% (better)
Growth
Revenue growth (TTM)12.8% (better)2.3%
Revenue growth, 5Y average9.7%35.3% (better)
Net income growth (TTM)15.6% (better)1.6%
EPS growth (TTM)18.4% (better)9.5%
EPS growth, 5Y average14.3%–
Profitability
Gross margin62.4% (better)60.1%
Operating margin32.0% (better)19.4%
Net margin25.0% (better)17.7%
FCF margin27.5%–
Return on equity74.2% (better)22.2%
Return on invested capital63.3% (better)19.7%
Financial health
Debt / equity0.28 (better)0.44
Net debt / EBITDA0.16 (better)−0.06
Interest coverage38.6× (better)15.3×
Current ratio1.173.06 (better)
Altman Z-score23.48 (better)5.52
Piotroski F-score8 (better)5
Dividends and buybacks
Buyback yield2.2%–
Shareholder yield2.2% (better)0.00%
Ownership
Held by institutions94.5%117%
Held by insiders0.29%2.3%
Insider net buying, 12 months−$58.4M–
Superinvestors holding3–
Short interest, % of float3.0%5.7%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.